Adeeb Ahmed, MD
Interventional Cardiology · Murfreesboro, TNNPI 1245217603
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Johnson & Johnson at 45.2% of the total. Reporting peaked in 2019 at $21,980 and has fallen 98.4% since, to $341 in 2025.
Across 207 payments — averaging $125.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$12K
- Regeneron$9K
- Penumbra, Inc.$1K
- AstraZeneca$1K
- Novartis$594
- Pfizer$246
- plus $2K from 22 others
What the payments were for
- Consulting fees$7,93831%
- Speaking & faculty fees$10,52541%
- Travel & lodging$3,22612%
- Food & beverage$4,24216%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 49 | $11,742 |
| Regeneron | 9 | $9,020 |
| Penumbra, Inc. | 4 | $1,392 |
| AstraZeneca | 13 | $1,321 |
| Novartis | 46 | $594 |
| Pfizer | 16 | $246 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $210 |
| Amgen | 10 | $201 |
| Heartflow, Inc. | 2 | $150 |
| Boehringer Ingelheim | 7 | $140 |
| Lundbeck LLC | 8 | $128 |
| Abbott | 1 | $111 |
| Edwards Lifesciences | 1 | $110 |
| Irhythm Technologies, Inc. | 1 | $105 |
| Regeneron Healthcare Solutions, Inc. | 5 | $90 |
| Vifor Pharma, Inc. | 4 | $69 |
| Tactile Systems Technology Inc | 2 | $45 |
| Philips North America LLC | 1 | $39 |
| Boston Scientific | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Pacira Pharmaceuticals Incorporated | 1 | $29 |
| Gilead | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Aegerion Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$10,938
- PRALUENT$8,788
- Indigo System$1,392
- FARXIGA$1,150
- FFRct$124
- DRAGONFLY OPSTAR$111
- Edwards SAPIEN 3 Transcatheter Heart Valve$110
- ZIO XT Patch$105
- Zio monitor$105
How this compares
$25,956 in reported general payments places this provider in the 80th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 336 | $315,624 |
| XareltoRivaroxaban | 74 | $83,738 |
| EntrestoSacubitril/Valsartan | 40 | $45,681 |
| BrilintaTicagrelor | 61 | $39,762 |
| Repatha SureclickEvolocumab | 45 | $31,171 |
| JardianceEmpagliflozin | 11 | $13,890 |
| Valsartan | 141 | $7,114 |
| Ranolazine ErRanolazine | 55 | $5,763 |
| Atorvastatin Calcium | 466 | $5,603 |
| Prasugrel Hcl | 18 | $4,594 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $4,437 |
| Rosuvastatin Calcium | 317 | $4,285 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 49 | $3,173 |
| ClopidogrelClopidogrel Bisulfate | 312 | $3,121 |
| Metoprolol Succinate | 276 | $3,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $246 | $315,624336 claims |
| Johnson & JohnsonXarelto | $11,742 | $83,73874 claims |
| NovartisEntresto | $594 | $45,68140 claims |
| AstraZenecaBrilinta | $1,321 | $39,76261 claims |
| Boehringer IngelheimJardiance | $140 | $13,89011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Murfreesboro
- Muhammad AzzouzMurfreesboro$15K
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
- Mehul PatelGermantown$382K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Ayaz RahmanKnoxville$251K
- Samuel HorrNashville$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.